Kasabach–Merritt phenomenon: a single centre experience
- 4 January 2010
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 84 (2), 97-104
- https://doi.org/10.1111/j.1600-0609.2009.01370.x
Abstract
OBJECTIVE: Kasabach-Merritt phenomenon (KMP) can lead to life-threatening bleeding, and its optimum treatment has not been established. We review the experience of managing KMP in a single institution. METHODS: A retrospective chart review on all children with KMP treated at the Hospital for Sick Children, Toronto, over an 18 yr period was carried out. RESULTS: All 15 patients had profound thrombocytopenia and hypofibrinogenemia at presentation, half had bleeding symptoms, and three had cardiac failure. All patients received corticosteroids. Five responded to steroids alone, given for an average of 13 wk, increasing platelets to >20 x 10(9)/L at a mean of 6.2 d and fibrinogen >1 g/dL at 25.6 d. Ten patients received at least one other therapeutic modality in addition to steroids, including vincristine, interferon, anti-platelet agents and pentoxifylline. Five patients received vincristine, for a mean of 6 wk, with two patients responding. Eight patients received interferon, for a mean of 4 months, with two patients responding. Overall, the mean time to increasing platelets >20 x 10(9)/L was 56 d, to >150 x 10(9)/L was 88 d and fibrinogen >1 g/dL 49 d. Ten patients showed a partial response to embolisation, with a mean of 2.8 procedures performed. Thrombotic complications occurred in 7%. Twelve patients remain alive, with relapse in six patients, all treated successfully. One patient died, and two patients have been lost to follow-up. CONCLUSION: KMP is a rare condition, with significant morbidity and mortality. The therapeutic approach should include a multidisciplinary team and consensus on guidelinesKeywords
This publication has 31 references indexed in Scilit:
- Low-Dose Metronomic Chemotherapy: Myth or Truth?Oncology Research and Treatment, 2006
- Vascular Integration of Endothelial Progenitors During Multistep Tumor ProgressionCell Cycle, 2006
- Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifyllineJournal of Pediatric Surgery, 2006
- Circulating Endothelial Progenitor Cells and Vascular AnomaliesLymphatic Research and Biology, 2005
- Kasabach–Merritt syndrome: caveats of diagnosis and managementCurrent Paediatrics, 2000
- Infants with Kasabach-Merritt syndrome do not have “true” hemangiomasThe Journal of Pediatrics, 1997
- Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferonJournal of Pediatric Surgery, 1993
- Successful treatment of Kasabach-Merritt syndrome with pentoxifyllineJournal of the American Academy of Dermatology, 1991
- Kasabach-Merritt syndromeJournal of Pediatric Surgery, 1988
- Kasabach-Merritt syndrome in infantsJournal of the American Academy of Dermatology, 1983